These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
577 related articles for article (PubMed ID: 9686920)
21. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Katz A; Van-Dijk DJ; Aingorn H; Erman A; Davies M; Darmon D; Hurvitz H; Vlodavsky I Isr Med Assoc J; 2002 Nov; 4(11):996-1002. PubMed ID: 12489489 [TBL] [Abstract][Full Text] [Related]
22. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946 [TBL] [Abstract][Full Text] [Related]
23. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes. Nosadini R; Brocco E Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531 [TBL] [Abstract][Full Text] [Related]
24. Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics. Wijnhoven TJ; Lensen JF; Rops AL; van der Vlag J; Kolset SO; Bangstad HJ; Pfeffer P; van den Hoven MJ; Berden JH; van den Heuvel LP; van Kuppevelt TH Am J Kidney Dis; 2006 Aug; 48(2):250-61. PubMed ID: 16860191 [TBL] [Abstract][Full Text] [Related]
25. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy. van den Born J; van Kraats AA; Bakker MA; Assmann KJ; Dijkman HB; van der Laak JA; Berden JH Diabetologia; 1995 Oct; 38(10):1169-75. PubMed ID: 8690168 [TBL] [Abstract][Full Text] [Related]
26. Complete remission of diabetic nephropathy in a type 1 diabetic patient with near-nephrotic range proteinuria and reduced renal function. Haraguchi K; Hara S; Ubara Y; Tanaka S; Nukui I; Shimura H; Ohashi K; Kobayashi T Diabetes Res Clin Pract; 2009 Mar; 83(3):295-9. PubMed ID: 19162360 [TBL] [Abstract][Full Text] [Related]
27. Distribution of the extracellular matrix components in human glomerular lesions. Büyükbabani N; Droz D J Pathol; 1994 Feb; 172(2):199-207. PubMed ID: 8169750 [TBL] [Abstract][Full Text] [Related]
28. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy. Makino H; Ikeda S; Haramoto T; Ota Z Nephron; 1992; 61(4):415-21. PubMed ID: 1501738 [TBL] [Abstract][Full Text] [Related]
29. Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Yokoyama H; Sato K; Okudaira M; Morita C; Takahashi C; Suzuki D; Sakai H; Iwamoto Y Kidney Int; 1999 Aug; 56(2):650-8. PubMed ID: 10432405 [TBL] [Abstract][Full Text] [Related]
30. [Immunohistochemical study on the extracellular matrix components in various renal diseases]. Chiba N Nihon Jinzo Gakkai Shi; 1991 Oct; 33(10):925-38. PubMed ID: 1770626 [TBL] [Abstract][Full Text] [Related]
31. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635 [TBL] [Abstract][Full Text] [Related]
32. Alterations in glomerular extracellular matrix components in glomerulonephritis. Ikeda S; Makino H; Ota Z Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):941-7. PubMed ID: 8255004 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy. Yokoyama H; Høyer PE; Hansen PM; van den Born J; Jensen T; Berden JH; Deckert T; Garbarsch C Diabetes; 1997 Nov; 46(11):1875-80. PubMed ID: 9356039 [TBL] [Abstract][Full Text] [Related]
34. [Altered glomerular mRNA expression of basement membrane components and type I collagen in diabetic rats treated with or without insulin therapy]. Fukui M Nihon Jinzo Gakkai Shi; 1991 Mar; 33(3):275-81. PubMed ID: 2062013 [TBL] [Abstract][Full Text] [Related]
35. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Rops AL; van den Hoven MJ; Veldman BA; Salemink S; Vervoort G; Elving LD; Aten J; Wetzels JF; van der Vlag J; Berden JH Nephrol Dial Transplant; 2012 Jul; 27(7):2853-61. PubMed ID: 22187315 [TBL] [Abstract][Full Text] [Related]
36. [Abnormality of type IV collagen metabolism in the development of diabetic nephropathy]. Haneda M; Kikkawa R Nihon Rinsho; 1992 Dec; 50(12):3016-20. PubMed ID: 1491453 [TBL] [Abstract][Full Text] [Related]
37. Differential distribution of type IV collagen chains in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus. Yagame M; Kim Y; Zhu D; Suzuki D; Eguchi K; Nomoto Y; Sakai H; Groppoli T; Steffes MW; Mauer SM Nephron; 1995; 70(1):42-8. PubMed ID: 7617116 [TBL] [Abstract][Full Text] [Related]
38. The effect of aminoguanidine on urinary heparan sulphate levels in experimental diabetes. Unlüçerçi YM; Bekpinar S; Seferoglu G Acta Diabetol; 2000; 37(2):71-6. PubMed ID: 11194930 [TBL] [Abstract][Full Text] [Related]
39. Changes in glomerular extracellular matrices components in diabetic nephropathy. Ikeda S; Makino H; Haramoto T; Shikata K; Kumagai I; Ota Z J Diabet Complications; 1991; 5(2-3):186-8. PubMed ID: 1770041 [TBL] [Abstract][Full Text] [Related]
40. Phenotypic expressions of type I, III, IV, V, and VI collagens in patients with diabetic nephropathy: immunohistochemical comparison between HD and non-HD patients. Kiryu K; Morita H; Fujita Y; Kawasumi M; Shinzato T; Tsuruta Y; Nakai S; Maeda K Nihon Jinzo Gakkai Shi; 1994 Apr; 36(4):365-73. PubMed ID: 8022109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]